Trial · NCT00454363

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

NCT00454363, Phase 2, Completed, National Cancer Institute (NCI); results first posted 2015-04-01

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer. Trials, record NCT00454363. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00454363

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
NCT number: NCT00454363
Status: Completed
Phases: Phase 2
Enrollment: 52 participants, actual
Lead sponsor: National Cancer Institute (NCI)
Conditions: Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Multiple Endocrine Neoplasia Type 1, Pancreatic Glucagonoma, Pancreatic Insulinoma, Pancreatic Polypeptide Tumor, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Pancreatic Neuroendocrine Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Somatostatin-Producing Neuroendocrine Tumor
Interventions: Laboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study
First posted: 2007-03-30
Last updated: 2020-04-03
Results first posted: 2015-04-01

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Objective Response Rate (Complete and Partial Response) for Each Cohort Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)	Up to 18 months	RECIST Criteria: Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): 30% decrease in sum of longest diameter (LD) of target lesions, reference baseline sum LD; Progressive Disease (PD): 20% increase in sum of LD of target lesions, reference smallest sum LD recorded since treatment started or appearance 1/\> new lesions; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, reference smallest sum LD since treatment started.
Secondary	Percent Change in Tumor Blood Flow Assessed by Functional CT	Baseline and week 12	Explore the effect on tumor blood flow as determined by functional CT of GW786034 (Pazopanib) 800 mg orally once daily on both arms, carcinoid and pNET.
Other	Progression Free Survival (PFS)	Baseline to 18 months.	PFS is defined as the duration of time from start of treatment to time of progression or death.
Other	Plasma Trough Level of GW786034	assessed at Baseline and day 28, day 28 reported

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Objective Response Rate (Complete and Partial Response) for Each Cohort Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)	Up to 18 months	RECIST best protocol response by intention to treat. Four participants were not evaluable for response.	participants	NUMBER
SECONDARY	Percent Change in Tumor Blood Flow Assessed by Functional CT	Baseline and week 12	Data were not collected from any participant in the Pazopanib + Carcinoid Arm Group	percentage of change in tumor blood flow	MEDIAN
OTHER_PRE_SPECIFIED	Progression Free Survival (PFS)	Baseline to 18 months.	Analysis calculated according to intent to treat.	months	MEDIAN
OTHER_PRE_SPECIFIED	Plasma Trough Level of GW786034	assessed at Baseline and day 28, day 28 reported	Plasma trough level in blood was below the level of detection.	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group13

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Objective Response Rate (Complete and Partial Response) for Each Cohort Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)	Pazopanib + Carcinoid	PR	0		participants
Objective Response Rate (Complete and Partial Response) for Each Cohort Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)	Pazopanib + pNET	PR	6		participants
Objective Response Rate (Complete and Partial Response) for Each Cohort Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)	Pazopanib + Carcinoid	SD	14		participants
Objective Response Rate (Complete and Partial Response) for Each Cohort Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)	Pazopanib + pNET	SD	21		participants
Objective Response Rate (Complete and Partial Response) for Each Cohort Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)	Pazopanib + Carcinoid	PD	3		participants
Objective Response Rate (Complete and Partial Response) for Each Cohort Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)	Pazopanib + pNET	PD	3		participants
Objective Response Rate (Complete and Partial Response) for Each Cohort Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)	Pazopanib + Carcinoid	Not Evaluable	3		participants
Objective Response Rate (Complete and Partial Response) for Each Cohort Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)	Pazopanib + pNET	Not Evaluable	1		participants
Percent Change in Tumor Blood Flow Assessed by Functional CT	Pazopanib + pNET		139	Full Range -56 to 154	percentage of change in tumor blood flow
Progression Free Survival (PFS)	Pazopanib + Carcinoid		12	95% Confidence Interval 3.4 to 20.6	months

1 to 10 of 13Source ClinicalTrials.gov

See all 13 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Pazopanib + Carcinoid	20
Overall Study	STARTED	Pazopanib + pNET	31
Overall Study	COMPLETED	Pazopanib + Carcinoid	15
Overall Study	COMPLETED	Pazopanib + pNET	29
Overall Study	NOT COMPLETED	Pazopanib + Carcinoid	5
Overall Study	NOT COMPLETED	Pazopanib + pNET	2

Source ClinicalTrials.gov

Adverse events135

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Abdominal distension	Gastrointestinal disorders	Pazopanib	2	51	4
other	Abdominal pain	Gastrointestinal disorders	Pazopanib	36	51	78
other	Acidosis	Metabolism and nutrition disorders	Pazopanib	2	51	4
other	Activated partial thromboplastin time prolonged	Blood and lymphatic system disorders	Pazopanib	5	51	10
other	Agitation	Psychiatric disorders	Pazopanib	1	51	1
other	Alanine aminotransferase increased	Metabolism and nutrition disorders	Pazopanib	19	51	58
other	Alkaline phosphatase increased	Metabolism and nutrition disorders	Pazopanib	9	51	28
other	Allergic rhinitis	Immune system disorders	Pazopanib	3	51	3
other	Alopecia	Skin and subcutaneous tissue disorders	Pazopanib	3	51	3
other	Anemia	Blood and lymphatic system disorders	Pazopanib	23	51	45

1 to 10 of 135Source ClinicalTrials.gov

See all 135 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Pazopanib
Total, other adverse events	Pazopanib	51	51
Total, serious adverse events	Pazopanib	16	51

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
25956795	DERIVED

Source PubMed

Grants2

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years	Source
P30CA016672	The University of Texas MD Anderson Cancer Center Support Grant (CCSG)	KOONG, ALBERT	UNIVERSITY OF TX MD ANDERSON CAN CTR	NATIONAL CANCER INSTITUTE	1985 to 2026	NIH RePORTER
U01CA062490	Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis	KUFE, DONALD W.	DANA-FARBER CANCER INST	NATIONAL CANCER INSTITUTE	1994 to 2013	NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00454363

GET https://conductscience.org/api/trials/v1/NCT00454363/events?page=2

API reference For AI assistants